Schizophrenia drug gets mixed results in IIb

Forest Laboratories and Hungary's Gedeon Richter says that high doses of its antipsychotic drug failed to demonstrate a statistically significant response in a Phase IIb trial, but low doses of RGH-188 reflected "nominally" significant results. Research will continue to determine if the therapy can work as a treatment for schizophrenia. A full set of data will be released in a few weeks, when analysts can get a better idea of what "nominally statistically significant" means.

- see the release for more information

Related Articles:
New schizophrenia drugs no better than generic. Report
Lilly's schizophrenia drug may offer breakthrough. Report
Forest Labs dumps failed stroke drug program. Report
Mice engineer to be schizophrenic. Report

Read more on: Forest Labs | Schizophrenia

Suggested Articles

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Canadian biotech AbCellera has nabbed a meaty $105 million series B funding round as it looks to boost its antibody work and seek out new potential me

Q32 Bio is working on treatments for autoimmune and inflammatory diseases that improve on systemic approaches.